Jerry A Shields
Overview
Explore the profile of Jerry A Shields including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
639
Citations
9502
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Bas Z, Dockery P, Lally S, Shields J, Shields C
Ophthalmic Plast Reconstr Surg
. 2023 Jan;
39(1):49-57.
PMID: 36598390
Purpose: To compare the clinical features at presentation and treatment outcomes of conjunctival melanoma by absence/presence of orbital invasion. Methods: A retrospective review of patients with conjunctival melanoma managed at...
12.
Dockery P, Ruben M, Duffner E, Levin H, Lally S, Shields J, et al.
Br J Ophthalmol
. 2022 Nov;
108(1):131-136.
PMID: 36414256
Background/aims: To evaluate the likelihood of germline mutation in patients presenting with solitary retinoblastoma based on tumour location at first examination. Methods: Retrospective analysis of solitary unilateral retinoblastoma for likelihood...
13.
Shields C, Dockery P, Mayro E, Bas Z, Yaghy A, Lally S, et al.
Saudi J Ophthalmol
. 2022 Oct;
36(3):308-314.
PMID: 36276251
Purpose: To understand conditional prognostic value of the Cancer Genome Atlas (TCGA) for uveal melanoma metastasis based on event-free survival at 1, 2, 3, 4, and 5 years. Methods: A...
14.
Negretti G, Kalafatis N, Shields J, Shields C
Ophthalmol Retina
. 2022 Aug;
7(2):171-177.
PMID: 35973646
Purpose: To determine the clinical features and outcomes of choroidal melanoma initially masquerading as central serous chorioretinopathy (CSCR). Design: Retrospective case series. Subjects: All patients with choroidal melanoma, initially misdiagnosed...
15.
Shukla A, Vaidya S, Yaghy A, Di Nicola M, Kaliki S, Fulco E, et al.
Eye (Lond)
. 2022 Apr;
37(5):938-946.
PMID: 35383310
Background/aims: To identify factors predictive of post-management secondary glaucoma in eyes with iris melanoma. Methods: Patients with iris melanoma who were conservatively managed on the Ocular Oncology Service, Wills Eye...
16.
Shields C, Kalafatis N, Gad M, Sen M, Laiton A, Silva A, et al.
Eye (Lond)
. 2022 Mar;
37(5):809-814.
PMID: 35306540
Metastasis to the eye can involve the choroid (90%), ciliary body (2%), iris (8%), and retina, optic disc, vitreous, and/or lens capsule (<1-4%). The mean number of uveal metastasis per...
17.
Shields C, Bas Z, Laiton A, Silva A, Sheikh A, Lally S, et al.
Eye (Lond)
. 2022 Feb;
37(5):815-822.
PMID: 35217824
In this review we discuss several recent concepts regarding retinoblastoma control and its impact. In a cohort of 482 patients with solitary unilateral retinoblastoma revealed germline mutation in 16% and...
18.
Lally S, Milman T, Orloff M, Dalvin L, Eberhart C, Heaphy C, et al.
Ophthalmology
. 2022 Jan;
129(6):679-693.
PMID: 35085662
Purpose: To evaluate targetable mutations and molecular genetic pathways in conjunctival melanoma with clinical correlation. Design: Observational case series. Participants: Patients with conjunctival melanoma. Main Outcome Measures: Mutational profile of...
19.
Jager M, Shields C, Cebulla C, Abdel-Rahman M, Grossniklaus H, Stern M, et al.
Nat Rev Dis Primers
. 2022 Jan;
8(1):4.
PMID: 35039549
No abstract available.
20.
Shields C, Shields J
Asia Pac J Ophthalmol (Phila)
. 2021 Jul;
10(4):341-342.
PMID: 34284457
No abstract available.